id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
ihlr-27435	Horwich, Allan; Brawley, Crista M.	Insider Trading in the Clinical Trial Setting	2023	57	.pdf	application/pdf	26853	1300	51	See, e.g., United States v. Kosinski, 976 F.3d 135, 141 (2d Cir. 2020) (alleging stock price dropped 58% after announcement of termination of clinical trial); Order Instituting Proceedings, In re Sweeney, Securities Exchange Act Release No. 95204 (July 7, 2022) (alleging that stock dropped 71% after disclosure of discontinuance of clinical trial); Order Instituting Proceedings at ¶ 6, In re Spector, Securities Exchange Act Release No. 95163 (June 27, 2022) (alleging, in clinical trial insider trading case, where company “had never generated revenues and depended on products then in development for future revenues” and the drug in question “was its lead product candidate, and the only one publicly identified as having advanced to the clinical trial stage of development,” stock dropped 75% when bad news was disclosed.). Recent developments in the law might be applied in connection with clinical trial information in ways that would not have been foreseen until recently.	cache/ihlr-27435.pdf	txt/ihlr-27435.txt